Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
About this study
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
- Condition
- Childhood ALL
- Sponsor
- French Africa Pediatric Oncology Group
Who can join
- Age
- Up to 18 years
- Sex
- All sexes
- Healthy volunteers
- Not stated
Inclusion 3
- Maximum age: 18 years
- Study condition: Childhood ALL
- Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2
Exclusion 1
- ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21
Where
3 sites, 3 recruiting
CHU de Treichville à ABIDJAN
Abidjan, Côte d’Ivoire
CHU Donka 030 BP 554
Conakry, Guinea
Hôpital Aristide Le Dantec, Avenue Pasteur,
Dakar, Senegal
Contact
-
Ndella Ms DIOUF, MD
00(221)77 656 49 13. ndella.diouf@gfaop.org
-
BRENDA Ms MALLON, MSc
0033142115411 brenda.mallon@gustaveroussy.fr
Potential match only. Final eligibility is determined by the study team.